Rani Therapeutics annual meeting elects all director nominees; ratifies Ernst & Young as auditor

Rani Therapeutics Holdings, Inc.

All 8 director nominees elected with substantial support; votes for each exceeded 226M, with withheld votes under 200K.
Ratification of Ernst & Young as independent auditor passed: 230,587,049 for, 51 against, 2,301 abstain.
Record date March 30, 2023: 25.4M Class A shares (1 vote each) and 24.1M Class B shares (10 votes each) outstanding.
No other proposals were considered; all matters approved as recommended by the board.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Rani Therapeutics Holdings, Inc. shareholders approved Ratification of the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-25 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-25

Exact text from the filing

The Company’s stockholders ratified the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, as follows: For: 230,587,049 Against: 51 Abstain: 2,301

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Rani Therapeutics Holdings, Inc. shareholders approved Election of director nominees to hold office until the 2024 annual meeting of stockholders at the 2023-05-25 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-25

Exact text from the filing

The Company’s stockholders elected the director nominees below, to hold office until the 2024 annual meeting of stockholders or until their successors are duly elected and qualified, as follows: For Withheld Broker Non-Votes Talat Imran 226,312,911 27,468 4,249,022 Mir Imran 226,125,068 215,311 4,249,022 Dennis Ausiello 226,152,615 187,764 4,249,022 Jean-Luc Butel 226,144,055 196,324 4,249,022 Laureen DeBuono 226,292,924 47,455 4,249,022 Andrew Farquharson 226,277,448 62,931 4,249,022 Malik Nanavaty 226,292,189 48,190 4,249,022 Lisa Rometty 226,314,568 25,811 4,249,022

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-024817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.